NCT07455643

Brief Summary

The development of advanced hybrid closed-loop (a-HCL) systems represents a significant step toward in improving glucose control and reducing user-dependent variability, especially In pediatric patients. Systems can automatically deliver correction boluses and modulate insulin delivery based on CGM feedback, thereby compensating for some of the consequences of human error. Current evidence suggests that a-HCL systems can tolerate unannounced carbohydrate loads up to approximately 20 g without compromising time in range (TIR) or safety. However, the metabolic response to larger or compositionally complex meals remains variable and highly dependent on the specific algorithm governing insulin delivery. Currently a variety of AID are commercially available: all of them present similarities and differences. The Medtronic MiniMed™ 780G uses a proportional-integral-derivative (PID) algorithm, a mathematical model that adjusts in real time insulin delivery rate based on 3 elements obtained from CGM reading values: the difference between the actual value and the chosen glucose target (proportional action), past values (integral action) and the glucose's rate of change (derivative action), In contrast, the Tandem t:slim X2™ with Control-IQ employs a model predictive control (MPC) algorithm, which aims, through a complex mathematical model, to predict glucose trends up to half-an-hour in the future, takin, also, in consideration actual and past glucose values. Despite sharing the same objective, said algorithms have different approaches, the former one being "reactive" and the latter "predictive". Therefore, their difference could result in different performances while facing mixed-nutrient meal or unannounced meals, defined as the consumptions of a meal with any prior insulin administration. Pediatric patients represent certainly a unique subgroup in which therapeutic adherence is a relevant issue, due to cognitive, developmental and behavioral factors. Understanding how different AID algorithms respond to unannounced meals in this age group is therefore crucial for optimizing safety and personalization of diabetes management. This study was designed to evaluate the strengths and limitations of two a-HCL systems, the Medtronic 780G (PID algorithm) and the Tandem t:slim X2 (MPC algorithm), in managing unannounced meals with different macronutrient compositions in children and adolescents with T1D. We also aim to better understand physiological and technological unannounced meal implications as to provide additional insight useful for the development of new fully closed loop algorithms, capable of minimizing glucose excursions and patient's burden.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 20, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2025

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

February 23, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 6, 2026

Completed
Last Updated

March 6, 2026

Status Verified

March 1, 2026

Enrollment Period

1 month

First QC Date

February 23, 2026

Last Update Submit

March 2, 2026

Conditions

Keywords

type 1 diabetes mellitusautomated insulin deliveryunannounced mealsproportional integral derivative controlmodel predictive control

Outcome Measures

Primary Outcomes (1)

  • Change in blood glucose concentration from pre-meal to two hours post-meal (2h-ΔBG), as measured by CGM in mg/dl

    Change in blood glucose concentration from pre-meal to two hours post-meal (2h-ΔBG), as measured by CGM

    from pre-meal to two hours post-meal

Secondary Outcomes (8)

  • Pre- and post-meal four-hour glucose difference (4h-ΔBG), as measured by CGM in mg/dl

    from pre-meal to four hour postprandial

  • Peak CGM value in mg/dl

    from pre-meal to four hour postprandial

  • Time to peak CGM value

    from pre-meal to four hour postprandial

  • Percentage of spent time in range (TIR, 70-180 mg/dL), as measured by CGM

    from pre-meal to four hour postprandial

  • Percentage of spent time in tight range (TITR, 70-140 mg/dL), as measured by CGM

    from pre-meal to four hour postprandial

  • +3 more secondary outcomes

Study Arms (2)

Announced meal (AM)

NO INTERVENTION

Participants followed their usual therapy while consuming both the "CHO meal" and the "mixed meal" three times each. In this phase, the carbohydrate content of each meal was announced to the insulin pump, and pre-meal boluses were delivered as per standard practice.

Unannounced meal (UM)

EXPERIMENTAL

Participants consumed the same meals, an equal number of times, without announcing their carbohydrate intake to the device. Consequently, no user-initiated boluses were administered during this period, and all insulin delivery adjustments were determined exclusively by the algorithm.

Other: Unannounced meal

Interventions

Participants consumed both the "CHO meal" and the "mixed meal" three times each, without announcing their carbohydrate intake to the device. Consequently, no user-initiated boluses were administered during this period, and all insulin delivery adjustments were determined exclusively by the algorithm.

Unannounced meal (UM)

Eligibility Criteria

Age11 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age between 11 and 18 years;
  • Type 1 diabetes diagnosed for at least 12 months;
  • Use of an A-HCL device for at least 3 months;
  • Proficiency in carbohydrate counting.

You may not qualify if:

  • Presence of malabsorption disorders;
  • Presence of chronic diabetes complications.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" - Catania

Catania, Sicily, 95123, Italy

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 23, 2026

First Posted

March 6, 2026

Study Start

April 20, 2025

Primary Completion

May 20, 2025

Study Completion

May 20, 2025

Last Updated

March 6, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations